| Today's Big NewsJan 4, 2023 |
|
The National Biotechnology and Biomanufacturing Initiative, which channels more than $2 billion to America’s biotech sector, will have far-reaching implications not only for the domestic biotech space but industries at large, including life sciences. Where are the salient opportunities? What are the gravest risks? Read this in-depth white paper from Randstad for answers. 
|
|
| By Max Bayer Moderna CEO Stéphane Bancel says data from the company's preclinical monkeypox, or mpox, vaccine are "fantastic," but don't expect to see it on the market any time soon, if at all. |
|
|
|
By Annalee Armstrong,Gabrielle Masson,Max Bayer Layoffs hit biotech fast and furious in 2022. The Fierce Biotech Layoff Tracker lists the reported events from January to December. |
By Nick Paul Taylor Roivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data that it claims position it as a best-in-class contender. |
By Annalee Armstrong Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and Genentech caught up in the wave with a multiple-year collaboration. |
|
Download this whitepaper for guidance on how to Scale your Direct-to-Consumer Microbiome Testing Company and when it makes sense to outsource microbiome sequencing to a third-party provider. 
|
|
By Nick Paul Taylor Eli Lilly has once again moved to bolster its gene therapy capabilities, committing $55 million upfront and $685 million in milestones to access Capsida Biotherapeutics’ adeno-associated virus engineering platform. |
By James Waldron Geron Corporation is on track to send its therapy for myelodysplastic syndrome to regulators this year after the telomerase inhibitor eased transfusion burden in a phase 3 trial. |
By Annalee Armstrong Gilead plans to work with EVOQ Therapeutics to hopefully bring to mind new treatments for autoimmune disorders in a deal worth up to $658.5 million. |
By Gabrielle Masson Hummingbird Bioscience and Synaffix are flocking together in a new licensing pact for a next-gen antibody drug conjugate program that gives Synaffix the chance to make up to $150 million. |
By Annalee Armstrong Merck KGaA eventually abandoned atacicept after trying again and again in multiple autoimmune disorders. Now, Vera Therapeutics has succeeded where the Big Pharma failed. |
By Max Bayer Merck KGaA is continuing its recent run of dealmaking, handing over an IL-12-targeting cancer med to PDS Biotech in a deal worth more than $120 million. The med is being tested as part of a triple combo therapy that also includes PDS Biotech's lead immunotherapy asset. |
By Fraiser Kansteiner As many in the U.S. struggle with rising costs of living, large pharmaceutical companies have opted to ring in the New Year with price hikes. |
By Andrea Park New year, new CEO. That’s the 2023 mantra for ReCor Medical, which kicked off the year with the appointment of a new leader. |
By Frank Diamond Abortion pills will now be available at retail pharmacies, according to a change in regulations governing how the medications can be dispensed that the Food and Drug Administration finalized yesterday. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
